Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2003 2
2004 2
2005 1
2006 1
2008 1
2009 20
2011 1
2012 1
2013 3
2014 3
2015 1
2018 4
2019 14
2020 7
2021 4
2022 6
2023 7
2024 8
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignass A, Ehehalt R, Germer CT, Grunert PC, Helwig U, Horisberger K, Herrlinger K, Kienle P, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators. Sturm A, et al. Z Gastroenterol. 2024 Aug;62(8):1229-1318. doi: 10.1055/a-2309-6123. Epub 2024 Aug 7. Z Gastroenterol. 2024. PMID: 39111333 Free article. German. No abstract available.
Malnutrition.
von Websky MW, Blumenstein I, Gerlach-Runge UA, Hausen A, Maasberg S, Vilz T. von Websky MW, et al. Among authors: blumenstein i. Visc Med. 2019 Oct;35(5):324-328. doi: 10.1159/000502868. Epub 2019 Aug 30. Visc Med. 2019. PMID: 31768397 Free PMC article. No abstract available.
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, Reinisch W, Iqbal T. Zoller H, et al. Among authors: blumenstein i. Gut. 2023 Apr;72(4):644-653. doi: 10.1136/gutjnl-2022-327897. Epub 2022 Sep 9. Gut. 2023. PMID: 36343979 Free PMC article. Clinical Trial.
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Sturm A, et al. Z Gastroenterol. 2022 Mar;60(3):332-418. doi: 10.1055/a-1713-3941. Epub 2022 Mar 9. Z Gastroenterol. 2022. PMID: 35263784 German. No abstract available.
Malnutrition and Intestinal Failure.
Lamprecht G, Blumenstein I. Lamprecht G, et al. Among authors: blumenstein i. Visc Med. 2019 Oct;35(5):281. doi: 10.1159/000503610. Epub 2019 Sep 26. Visc Med. 2019. PMID: 31768390 Free PMC article. No abstract available.
Framework of IBD Care Delivery Across Ages.
Delen S, Jaghult S, Blumenstein I, Pouillon L, Bossuyt P. Delen S, et al. Among authors: blumenstein i. J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii55-ii66. doi: 10.1093/ecco-jcc/jjae093. J Crohns Colitis. 2024. PMID: 39475083 Free PMC article.
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panés J, Danese S, Hisamatsu T, Terry NA, Salese L, Van Rampelbergh R, Sahoo A, Vetter ML, Yee J, Han C, Frustaci ME, Wan KYY, Yang Z, Johanns J, Andrews JM, D'Haens GR, Sands BE; GALAXI 2 & 3 Study Group. Panaccione R, et al. Lancet. 2025 Jul 26;406(10501):358-375. doi: 10.1016/S0140-6736(25)00681-6. Epub 2025 Jul 17. Lancet. 2025. PMID: 40684778 Clinical Trial.
90 results